Itgb3-integrin-deficient mice may not be a sufficient model for patients with Glanzmann thrombasthenia

Mol Med Rep. 2021 Jun;23(6):449. doi: 10.3892/mmr.2021.12088. Epub 2021 Apr 21.

Abstract

Itgb3‑integrin‑deficient (Itgb3‑/‑) mice have been reported as a Glanzmann thrombasthenia (GT) model and have been used for platelet research. However, it remains unclear whether this mouse model can fully simulate patients with GT or whether it has different characteristics from these patients. The present study aimed to answer this question. Itgb3‑/‑ mice were tested for platelet function, tail bleeding, whole‑blood count, bone marrow hematopoiesis and organ enlargement. Itgb3‑/‑ platelets showed impaired functions, including fibrinogen binding, aggregation, adhesion or spreading. Itgb3‑/‑ mice demonstrated decreased platelet count and microcytic hypochromic anemia. Reduced iron staining of bone marrow and decreased plasma ferritin level confirmed the diagnosis of iron deficiency anemia. Evident splenomegaly was observed in Itgb3‑/‑ mice. Immunohistochemical analysis of spleen biopsy revealed normal expression of CD3 and CD19, but elevated expression of CD71, which suggested that the splenomegaly in Itgb3‑/‑ mice may be associated with extramedullary hematopoiesis. In conclusion, Itgb3‑/‑ mice exhibited some unique characteristics that differed from those of human patients with GT and thus cannot completely simulate patients with GT.

Keywords: tgb3‑integrin‑deficient mice; Glanzmann thrombasthenia; plenomegaly; extramedullary hematopoiesis; mouse model.

MeSH terms

  • Anemia
  • Animals
  • Blood Platelets / metabolism
  • Disease Models, Animal
  • Female
  • Hematopoiesis
  • Humans
  • Integrin beta3 / genetics*
  • Integrin beta3 / metabolism*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Platelet Function Tests
  • Spleen
  • Splenomegaly
  • Thrombasthenia / genetics*
  • Thrombasthenia / metabolism*
  • Transcriptome

Substances

  • ITGB3 protein, human
  • Integrin beta3

Grants and funding

The present study was funded by The National Natural Science Foundation of China (grant no. 81700130), Natural Science Foundation of Jiangsu Province of China (grant no. BK20150474), The Science and Technology Commission of Zhenjiang Municipality (grant no. SH2017006), Novo Nordisk Haemophilia Research Fund in China and Youth Medical Talents Project of ‘Ke Jiao Qiang Wei’ project of Jiangsu province (grant no. QNRC201684).